



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

Asymmetric Synthesis of (R)-(-)-Rhododendrol, the Aglycone of the Hepatoprotective Agent Rhododendrin

Gowravaram Sabitha^a, B. Thirupathaiah^a & J. S. Yadav^a

^a Organic Division I, Indian Institute of Chemical Technology, Hyderabad, India

Published online: 22 May 2007.

To cite this article: Gowravaram Sabitha, B. Thirupathaiah & J. S. Yadav (2007) Asymmetric Synthesis of (R)-(-)-Rhododendrol, the Aglycone of the Hepatoprotective Agent Rhododendrin, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 37:10, 1683-1688, DOI: [10.1080/00397910701265614](https://doi.org/10.1080/00397910701265614)

To link to this article: <http://dx.doi.org/10.1080/00397910701265614>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Asymmetric Synthesis of (*R*)-(–)-Rhododendrol, the Aglycone of the Hepatoprotective Agent Rhododendrin

Gowravaram Sabitha, B. Thirupathaiah, and J. S. Yadav

Organic Division I, Indian Institute of Chemical Technology,
Hyderabad, India

Abstract: Starting from 2,3-*O*-isopropylidene-D-glyceraldehyde (**3**) as chiral material, (*R*)-(–)-rhododendrol **2**, the aglycone of the naturally occurring rhododendrin **1** was synthesized.

Keywords: aglycone, melanin inhibitor, natural product, rhododendrin, rhododendrol

INTRODUCTION

The glycoside rhododendron, along with its aglycone rhododendrol, was isolated for the first time from leaves of *Rhododendron chrysanthum* Linn. in 1901.^[1] Later Khan et al.^[2] isolated rhododendrin as the major component of the aqueous extract of the leaves of *Taxus baccata* L., which possessed good tranquilizing activity.^[3] This glycoside was also isolated from the bark of the white birch, *Betula alba* L.,^[4] and from *Rhododendron fauriae* var. *rufescens*.^[5] More recently, rhododendrin was found in *Bergenia*,^[6] *Abies webbiana* Lindl.,^[7] *Rhodiola*,^[8] *Alnus glutinosa* Gaertn.,^[9] and *Cotyledon wallichii*.^[10] Recently, rhododendrol and its glycoside have been used as a melanin inhibitor and in skin-lightening cosmetics.^[11] Rhododendrin exhibited hepatoprotective activity against two hepatotoxins in rats. The aglycone (–)-rhododendrol is


Received August 21, 2007

IICT Communication No. 060333.

Address correspondence to Gowravaram Sabitha, Organic Division I, Indian Institute of Chemical Technology, Hyderabad 500 007, India. E-mail: gowravaramsr@yahoo.com

found to co-occur in many species. It has been unequivocally established that the carbohydrate moiety is attached via the aliphatic hydroxyl group.^[12]

From X-ray diffraction studies, the absolute configuration at the chiral center in the aglycone portion has been found to be *R*.^[13] Syntheses of (*R*)-(-)-rhododendrol by enantioselective addition of diallyl zinc to an aldehyde using chiral tricarbonyl chromium (0) catalyst^[14a] and resolution of racemic rhododendrol by lipase-catalyzed enantioselective acetylation^[14b] were reported. In continuation of our studies on the synthesis of biologically active molecules,^[15] we herein report a simple and practical synthesis of (*R*)-(-)-rhododendrol from a chiral pool material.




RESULTS AND DISCUSSION

The chiral center in the molecule can be elaborated from (*R*)-isopropylidene glyceraldehyde (**3**), which can easily be synthesized from oxidative cleavage of readily available 1,2:5,6-di-*O*-isopropylidene-D-mannitol.^[16] The (*R*)-acetone **3** thus synthesized from D-mannitol on a large scale, was subjected to the Wittig reaction^[17] with 4-benzyloxybenzylphosphonium bromide to give a mixture of *Z* and *E* olefin (6:4) **4** in an overall yield of 80%. Hydrogenation of compound **4** (mixture of *Z* and *E* olefin) over 10% Pd/C gave a saturated compound **5** in 78% yield in which simultaneously debenzoylation also occurred. Thus, the protection of phenolic -OH was carried out using benzyl bromide to afford benzyl ether **6**. Hydrolysis of the acetone afforded diol **7** in 92% yield. Selective tosylation of the primary hydroxyl group of **7** with TsCl in dry pyridine produced tosylate **8** in 80% yield, and further reduction with lithium aluminium hydride (LAH) in THF afforded mono hydroxy compound **9**. Finally, the synthesis of target molecule **2** was achieved in 85% yield by debenzoylation using Pd/C. The physical (mp), optical rotation [α_D -17.4 (c 0.5, MeOH) lit.^[13] α_D -17 (c 0.5, MeOH)], and spectral data (¹H NMR, ¹³C NMR, and mass) are identical to those of the natural product (Scheme 1).

In conclusion, we have developed a synthetic route for the synthesis of (*R*)-(-)-rhododendrol from a chiral source.

EXPERIMENTAL

All solvents were distilled before use. Dry solvents were prepared according to the standard procedures. All reactions were carried out under an N₂



Scheme 1. Reagents and conditions: a) $[\text{BnOC}_6\text{H}_4\text{CH}_2\text{Ph}_3\text{P}]^+\text{Br}^-$ (1.0 eq), *n*-BuLi (1.0 eq), THF, 0°C , 2 h, 80%; b) H_2 , 10% Pd-C, MeOH, rt, on, 78%; c) PhCH_2Br , acetone, K_2CO_3 , TBAI, rt, 6 h, 88%; d) PTSA, MeOH, 3 h, rt, 92%; e) TsCl (1.1 eq), dry DCM, DMAP, 0°C , 4 h, 80%; f) LAH, THF, 0°C to rt, 6 h, 78%; g) H_2 , 10% Pd-C, MeOH, rt, on, 85%.

atmosphere and monitored by thin-layer chromatography (TLC) on silica gel (60–120 mesh, Merck). NMR spectra were recorded on Bruker (300 MHz ^1H ; 75 MHz ^{13}C) and Varian (200 MHz ^1H ; 50 MHz ^{13}C) NMR spectrometers using CDCl_3 as solvent. ESI-mass spectra were recorded with LC-MSD-Trap-SL (Agilent Technologies). IR spectra were recorded with FTIR (Thermo Nicolet Nexus 670 spectrometer). Optical rotations were measured with Jasco DIP-370 polarimeter at 20°C .

(4*S*)-4-[(*E*)-2-[4-(Benzyloxy)phenyl]-1-ethenyl]-2,2-dimethyl-1,3-dioxolane (4)

To a solution of Wittig salt, 4-benzyloxybenzylphosphonium bromide (9.17 g, 1.2 eq, 19.99 mmol) in dry THF (20 ml) under N_2 at 0°C , *n*-butyl lithium (12.5 ml, 1.6 M) was added dropwise at 0°C . Immediately the solution became red. After 30 min, the solution of aldehyde **3** (3 g, 16.66 mmol) in dry THF was added at 0°C and allowed to stir for 3–4 h. Then, the reaction mixture was filtered and extracted with ethyl acetate, dried over Na_2SO_4 , concentrated on vacuum, and purified by silica-gel column chromatography to get a mixture of *Z* and *E* olefin **4** (6:4) (4.6 g, 80%). Data for *Z*-olefin: IR (KBr): 3025, 2986, 1607, 1511, 1379, 1245, 1062, 844 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): δ 1.39 (s, 3H), 1.48 (s, 3H) 3.64 (t, $J = 7.8\text{ Hz}$, 1H), 4.12 (dd, $J = 6.2, 7.8\text{ Hz}$,

1H), 4.81–4.93 (m, 1H), 5.10 (s, 2H), 5.60 (dd, $J = 9.3, 11.7$ Hz, 1H), 6.62 (d, $J = 11.7$ Hz, 1H), 6.95 (d, $J = 8.5$ Hz, 2H), 7.20 (d, $J = 8.5$ Hz, 2H), 7.26–7.48 (m, 5H). FAB mass: 310 (M^+).

4-{2-[(4*S*)-2,2-Dimethyl-1,3-dioxolan-4-yl]ethyl}phenol (5)

Compound **4** (5 g, 16.12 mmol) was dissolved in MeOH (40 mL), then cat. 10% Pd/C was added and hydrogenated overnight. Then the reaction mixture was filtered, and MeOH was removed in vacuo. The residue was purified by column chromatography using silica gel to afford the saturated compound **5** (2.8 g, 78%). $[\alpha]_D^{25}$: +4.4 ($c = 0.015$, MeOH). IR (KBr): 3391, 3012, 2986, 1515, 1375, 1217, 1064 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): δ 1.34 (s, 3H), 1.39 (s, 3H), 1.69–2.02 (m, 2H), 2.47–2.86 (m, 2H), 3.42–3.61 (m, 1H), 3.80–4.05 (m, 2H), 6.65 (d, $J = 8.4$ Hz, 2H), 7.00 (d, $J = 8.4$ Hz, 2H), 8.45 (s, -OH). ^{13}C NMR (75 MHz, CDCl_3): 27.8, 28, 30, 34, 75, 79, 108, 115, 129, 133, 155. LCMS: 221 ($M-1$). Anal. calcd. for $\text{C}_{13}\text{H}_{18}\text{O}_3$ (222.28): C, 70.25; H, 8.16. Found: C, 68.58; H, 7.70.

(4*S*)-4-[4-(Benzyloxy)phenethyl]-2,2-dimethyl-1,3-dioxolane (6)

To a stirred solution of compound **5** (10 g, 81.96 mmol) in dry acetone (80 mL), K_2CO_3 (4 eq, 45.2 g) was added at room temperature under N_2 . After 30 min, benzyl bromide (1 eq, 9.74 mL) was added slowly, followed by the addition of a catalytic amount of TBAI, and the reaction mixture was allowed to stir for 6 h at room temperature. Acetone was removed under vacuum, and the residue was extracted with ethyl acetate, dried over Na_2SO_4 , and concentrated. The crude product was purified by silica-gel column chromatography to afford compound **6** (15.2 g, 88%). $[\alpha]_D^{25}$: +7.3 ($c = 0.015$, MeOH). IR (KBr): 3031, 2985, 1610, 1510, 1239, 1065, 847 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): δ 1.32 (s, 3H), 1.38 (s, 3H), 1.67–2.01 (m, 2H), 2.51–2.82 (m, 2H), 3.83–4.13 (m, 3H), 5.01 (s, 2H), 6.84 (d, $J = 8.3$ Hz, 2H), 7.06 (d, $J = 8.3$ Hz, 2H), 7.24–7.39 (m, 5H). ^{13}C NMR (75 MHz, CDCl_3): 29, 36, 69, 70, 75, 106, 114, 128–132 (8C), 156. LCMS: 313 ($M+1$). Anal. calcd. for $\text{C}_{20}\text{H}_{24}\text{O}_3$ (312.40): C, 76.89; H, 7.74. Found: C, 74.17; H, 7.31.

(2*S*)-4-[4-(Benzyloxy)phenyl]butane-1,2-diol (7)

To a solution of compound **6** (4 g, 12.82 mmol) in MeOH, a catalytic amount of PTSA was added and allowed to stir for 3 h at room temperature. MeOH was removed under vacuum, then the residue was extracted with ethyl acetate and dried over Na_2SO_4 . The crude product was purified by column chromatography to get compound **7** (3.2 g, 92%). $[\alpha]_D^{25}$: –16.0 ($c = 0.015$, MeOH). IR (KBr): 3371, 3037, 2925, 1611, 1511, 1102, 1015, 813, 736,

695 cm^{-1} . ^1H NMR (200 MHz, CDCl_3 + DMSO): δ 1.56–1.67 (m, 2H), 2.49–2.79 (m, 2H), 3.25–3.59 (m, 3H), 3.90–3.97 (d, J = 5.4 Hz, 2H), 5.02 (s, 2H), 6.82 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 7.26–7.42 (m, 5H). ^{13}C NMR (50 MHz, CDCl_3): 29, 34, 65, 68, 72, 113, 128–133 (8C), 155. LCMS: 295 (M + Na). Anal. calcd. for $\text{C}_{17}\text{H}_{20}\text{O}_3$ (272.34): C, 74.97; H, 7.40. Found: C, 73.52; H, 6.71.

(2S)-4-[4-(Benzyloxy)phenyl]-2-hydroxybutyl 4-methyl-1-benzene Sulfonate (8)

p-Toluene sulphonyl chloride (1 eq) and a catalytic amount of DMAP were added to a stirred solution of compound **7** (2 g, 7.35 mmol) in dry DCM at 0°C and left stirring for 4 h. Then the reaction mixture was extracted with DCM, concentrated under vacuum, dried over Na_2SO_4 , and purified by column chromatography to give compound **8** (2.3 g, 80%). $[\alpha]_{\text{D}}^{25}$: +6.6 (c = 0.0075, MeOH). IR (KBr): 3568, 3034, 2924, 1608, 1512, 1351, 1174, 1090, 949 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): δ 1.58–1.76 (m, 2H), 2.45 (s, 3H), 2.54–2.74 (m, 2H), 3.72–3.81 (m, 1H), 3.86 (t, J = 9.8 Hz, 1H), 3.98 (dd, J = 3.0, 9.8 Hz, 1H), 5.02 (s, 2H), 6.82 (d, J = 8.3 Hz, 2H), 7.02 (d, J = 8.3 Hz, 2H), 7.26–7.40 (m, 7H), 7.76 (d, J = 8.3 Hz, 2H). LCMS: 449 (M + Na). Anal. calcd. for $\text{C}_{24}\text{H}_{26}\text{O}_5\text{S}$ (426.52): C, 67.58; H, 6.14. Found: C, 67.45; H, 6.63.

(2R)-4-[4-(Benzyloxy)phenyl]butan-2-ol (9)

To a suspension of lithium aluminium hydride (0.3 g, 2 eq) in dry THF, compound **8** (2 g, 4.69 mmol) was added, and the reaction mixture was allowed to stir at 0°C, then brought to room temperature, and stirred for 6 h. The reaction mixture was filtered and extracted with ethyl acetate, dried over Na_2SO_4 , and concentrated, and the residue was purified by column chromatography to furnish compound **9** (0.84 g, 78%). IR (KBr): 3310, 3035, 1512, 1245, 1175, 1012, 738, 695 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): δ 1.24 (d, J = 6.0 Hz, 3H), 1.70–1.78 (m, 2H), 2.57–2.76 (m, 2H), 3.75–3.86 (m, 1H), 5.05 (s, 2H), 6.86 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.3 Hz, 2H), 7.30–7.44 (m, 5H); LCMS: 279 (M + Na).

4-(3-Hydroxy-butyl)-phenol [(R)-(-)-rhododendrol] (2)

To a solution of compound **9** (1.5 g, 5.8 mmol) in MeOH, cat. 10% Pd/C was added and hydrogenated overnight. Then the reaction mixture was filtered, and filtrate was concentrated in vacuo. The residue was purified by silica-gel column chromatography to afford the target molecule **2** as a colorless solid (0.826 g, 85%), mp 80°C, lit.^[13] 79–80°C. $[\alpha]_{\text{D}} -17.4$ (c 0.5, MeOH)

lit.^[13] α_D-17 (c 0.5, MeOH). IR (KBr): 3367, 3067, 2931, 1614, 1515, 1240, 1071, 819 cm^{-1} . ^1H NMR (200 MHz, $\text{CDCl}_3 + \text{DMSO}$): δ 1.16 (d, $J = 5.8$ Hz, 3H), 1.58–1.75 (m, 2H), 2.44–2.71 (m, 2H), 3.46 (bs, 1H), 3.62–3.76 (m, 1H), 6.67 (d, $J = 8.0$ Hz, 2H), 6.95 (d, $J = 8.0$ Hz, 2H), 8.46 (s, 1H). ^{13}C NMR: (50 MHz, $\text{CDCl}_3 + \text{DMSO}$): 30, 39, 40.5, 65.9, 114, 128, 133, 154. EI-MASS: 166 (M^+), 148, 133, 107 (100%).

ACKNOWLEDGMENT

B. T. thanks Council for Scientific and Industrial Research (CSIR), New Delhi, for the award of a fellowship.

REFERENCES

1. Archangelsky, K. *Arch. Exp., Pathol. Pharmacol.* **1901**, 46, 313.
2. Khan, M. S. Y.; Kumar, I.; Prasad, J. S.; Nagarajan, G. R.; Parthasarathy, M. R.; Krishnamurthy, H. G. *Planta. Med.* **1976**, 30, 82.
3. Vohora, S. B.; Kumar, I. *Planta. Med.* **1971**, 2, 100.
4. (a) Sosa, A. C. R. *Hebd. Seances Acad. Sci.* **1933**, 196, 1827; (b) Sosa, A. *Ann. Chim. (Paris)* **1940**, 14, 5.
5. Kawaguchi, R.; Kim, K. G.; Kim, H. K. *J. Pharm. Soc. Jpn.* **1942**, 62, 4.
6. (a) Thieme, H.; Winkler, H. J. *Pharmazie* **1969**, 24, 703; (b) Thieme, H.; Walewska, E.; Winkler, H. J. *Pharmazie* **1969**, 24, 648.
7. Chakraborty, K.; Nandt, A.; Poddar, G.; Pyrek, J. S. *Fitoterapia* **1987**, 58, 56.
8. Barnaulov, O. D.; Limarenko, A. Y.; Kurkin, V. A.; Zapesochaya, G. G.; Shchalinskii, A. N. *Khim. Farm. Zh.* **1986**, 20, 1107.
9. Klisches, M.; Zenk, M. H. *Phytochemistry* **1978**, 17, 1281.
10. Van Rooyen, G. F.; Pietersee, M. J.; Brink, C. V. D. M. *J. S. Afr. Chem. Inst.* **1967**, 20, 54.
11. (a) Ikemoto, T.; Nakatsugawa, H.; Yokota, T. Japan Patent 98182410; *Chem. Abstr.*, **1998**, 129, 153002; (b) Fujiwara, H.; Ishizumi, A.; Kobayashi, A.; Kobayashi, Y.; Naeshino, E.; Yoshikawa, M. Japan Patent 98236940; *Chem. Abstr.*, **1998**, 129, 265188f.
12. Zemplén, G.; Bagnar, R.; Boskovitz, L. *Ber.* **1944**, 77, 784.
13. Parmar, V. S.; Vardhan, A.; Taneja, P.; Sinha, R.; Patnaik, G. K.; Tripathi, G. S. C.; Boll, P. M.; Larsen, S. J. *Chem. Soc., Perkin Trans. 1* **1991**, 2687.
14. (a) Jones, G. B.; Heaton, S. B. *Tetrahedron. Asymmetry* **1993**, 4 (2), 261; (b) Yuasa, Y.; Shibaya, S.; Yuasa, Y. *Synth. Commun.* **2003**, 33 (9), 1469.
15. (a) Sabitha, G.; Srinivas Reddy, Ch.; Srihari, P.; Yadav, J. S. *Synthesis* **2003**, 2699; (b) Sabitha, G.; Swapna, R.; Satheesh Babu, R.; Yadav, J. S. *Tetrahedron Lett.* **2005**, 46, 6145; (c) Sabitha, G.; Sudhakar, K.; Mallikarjun Reddy, N.; Rajkumar, M.; Yadav, J. S. *Tetrahedron Lett.* **2005**, 46, 6567; (d) Sabitha, G.; Srinivas Reddy, Ch.; Yadav, J. S. *Tetrahedron Lett.* **2006**, 47, 4513.
16. Schmid, C. R.; Bryant, J. D.; Dowlatzedah, M.; Phillips, J. L.; Prather, D. E.; Schantz, R. D.; Sear, N. L.; Vianco, C. S. *J. Org. Chem.* **1991**, 56, 4056.
17. Lee, J.; Hung, J. J. *J. Org. Chem.* **2004**, 69 (19), 6433.